Buying Provigil online from Discount-Canadian-Meds.com
is quick and easy.
To order, simply choose the strength you are
taking below, add the package size and version of Provigil (brand or generic) that you want to your cart and follow the easy checkout procedure.
Click on one of the drugs below to view pricing
information.
Provigil
Important Note: Please remember that Provigil is
a prescription medication and should only be taken under
the supervision of a licensed physician. There is no such
thing as an "online consultation" and nothing
can replace visiting your doctor in person.
Provigil
is an FDA approved medication indicated to improve
wakefulness in patients with excessive sleepiness and help
treat the following sleep disorders:
In these conditions it is common to feel sleepy during the day (or at night if you work night shifts) and/or to
have uncontrollable sleep attacks, even at inappropriate times e.g., when eating, talking etc.
This medicine treats the symptoms of sleepiness. Other treatments intended to help your underlying
medical condition should still be used regularly, unless your doctor tells you otherwise.
Yahoo! News Search Results for Provigil
Yahoo! News Search Results for Provigil
Cephalon 2Q net income rises 5 percent
Biotechnology company Cephalon Inc. said Tuesday its second-quarter net income rose 5 percent on a boost in sales of the sleep disorder drug Provigil and the cancer drug Treanda.
Cephalon Q2 Profit Up 5%; Lifts FY10 View, Guides Q3 - Update
Drug maker Cephalon, Inc. , Tuesday reported a 5% increase in second quarter profit help primarily by strong sales of its sleep disorder drugs Provigil and Nuvigil, and cancer drug Treanda. Cephalon said it expects to record third quarter earnings above estimates, and lifted its annual outlook from the prior level.
Don't Sleep Through Cephalon's Growth
By Ockham Research Staff. Cephalon ( CEPH ) is a biopharmaceutical company that we have highlighted in the past, and they reported another outstanding quarter after the close on Tuesday. The company's most successful drug is Provigil, which is used to treat some sleep disorders, but for some reason we think the market has been lulled into sleepiness when it comes to this growth story. Read more ...
Use of Cephalon's Provigil could be limited in Europe
European health regulators recommended on Thursday restricting the use of Cephalon's sleep disorder drug Provigil for treating narcolepsy only, over concerns that risks may outweigh the benefits of the medicine in other uses.
Strong Quarter for Cephalon
Cephalon Inc. delivered another strong quarter with second quarter earnings coming in at $2.05 per share, six cents above the Zacks Consensus Estimate and well above the year-ago earnings of $1.44 per share.
Snooze And You Miss A Great Buy In Cephalon
We think Cephalon is a growth stock that even a value investor can appreciate, and investors with a
FTC Defends Its Role in Watson-Cephalon Investigation
The battle between the FTC and Watson Pharmaceuticals over whether the generics maker engaged in an anti-competitive deal with brand-name pharmaceutical company Cephalon continues as the FTC fires off responses defending its actions. The FTC has argued throughout subpoena enforcement proceedings that it was simply investigating whether a reverse-payment settlement between Watson and Cephalon ...
Cephalon's 2nd-quarter income beats estimates
Cephalon Inc reported second-quarter net income rose to $165 million from $110 million a year ago, as revenues jumped 32 percent.
Cephalon Reports Record Sales and Earnings in Second Quarter 2010
FRAZER, Pa., July 27 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported second quarter 2010 sales of $712.4 million, a 32 percent increase compared to sales of $539.0 million for the second quarter 2009. Basic income per common share for the quarter was $1.18. Excluding amortization expense and certain other items, basic adjusted income per common share for the quarter was $2 ...
How to Rebuild Your Attention Span and Focus [Focus]
# focus Most people who click on this article won't finish reading it. So says Nick Carr . The New York Times will remind you that you'll probably forget it in a few minutes . This idea's so prevalent, even the Onion has started taking jabs. More »
Newsfeed display by CaRPHome
